Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat
Abstract Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat is glucuronidation, mainly catalyzed by uridine diphosphate‐glucuronosyltransferase (...
Main Authors: | Sebastian Frechen, Ibrahim Ince, André Dallmann, Michael Gerisch, Natalia A. Jungmann, Corina Becker, Maximilian Lobmeyer, Maria E. Trujillo, Shiyao Xu, Rolf Burghaus, Michaela Meyer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13059 |
Similar Items
-
Effects of Andrographis paniculata extract on uridine diphosphate-glucuronosyltransferase activity
by: Norzainah Ahmad, et al.
Published: (2005-01-01) -
Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant
by: H. S. Ciftci, et al.
Published: (2018-10-01) -
Revisiting the Latency of Uridine Diphosphate-Glucuronosyltransferases (UGTs)—How Does the Endoplasmic Reticulum Membrane Influence Their Function?
by: Yuejian Liu, et al.
Published: (2017-08-01) -
Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin
by: Chen Hong, et al.
Published: (2022-03-01) -
Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics
by: Corina Becker, et al.
Published: (2022-11-01)